Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on April 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Judith Matthews appointed CFO, Corporate Secretary and Treasurer effective June 1, 2026.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Judith Matthews appointed CFO, Corporate Secretary and Treasurer effective June 1, 2026
- James Gruber remains through May 31, 2026, then transitions to a six-month consulting agreement
- Annual base salary $440,000 with target discretionary bonus of 45% of base salary
- One-time option grant for 37,000 shares, vesting in equal annual installments over four years
- Planned transition supports continuity while adding executive compensation and equity dilution exposure
Item 7.01 · Regulation FD Disclosure
- Eton announced Ms. Matthews’ appointment on April 16, 2026
- Exhibit 99.1 contains the press release with appointment details
- Leadership change may affect Eton’s strategic execution and investor outlook
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.